Document Detail


Addiction to c-MYC in multiple myeloma.
MedLine Citation:
PMID:  22806891     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
In multiple myeloma, c-MYC is activated and contributes to the malignant phenotype. Targeting c-MYC by short hairpin RNA induced cell death in myeloma cell lines however; cell lines are generated from samples taken in advanced stages of the disease and may not reflect patient cells adequately. In this study we used the selective small molecule inhibitor of MYC-MAX heterodimerization, 10058-F4, on myeloma cell lines as well as primary myeloma cells, and show that inhibition of c-MYC activity efficiently induces myeloma cell death. Moreover, in cocultures of cell lines with bone marrow stromal cells from myeloma patients, the inhibitor still induces apoptosis. Our results provide further evidence that myeloma cells are addicted to c-MYC activity and that c-MYC is a promising therapeutic target in multiple myeloma.
Authors:
Toril Holien; Thea Kristin Våtsveen; Hanne Hella; Anders Waage; Anders Sundan
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-7-17
Journal Detail:
Title:  Blood     Volume:  -     ISSN:  1528-0020     ISO Abbreviation:  -     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-7-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
KG Jebsen Center for Myeloma Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway;
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  ICAM-1-activated Src and eNOS signaling increase endothelial cell surface PECAM-1 adhesivity and neu...
Next Document:  Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lym...